Welcome to our dedicated page for LB Pharmaceuticals news (Ticker: LBRX), a resource for investors and traders seeking the latest updates and insights on LB Pharmaceuticals stock.
LB Pharmaceuticals Inc (NASDAQ: LBRX) generates news primarily around the clinical and corporate progress of its lead drug candidate, LB-102, and its activities as a clinical-stage biopharmaceutical company in neuropsychiatry. The company focuses on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, and its updates often reflect key milestones in this development path.
Investors and observers following LBRX news can expect coverage of clinical trial results and plans, such as the company’s reported positive data from a four-week, placebo-controlled, double-blinded Phase 2 trial of LB-102 in acute schizophrenia and its stated plans to advance LB-102 into a Phase 3 trial for acute schizophrenia and a Phase 2 trial for bipolar depression. News items also highlight scientific presentations at medical conferences, where LB Pharmaceuticals has discussed primary efficacy, safety, and exploratory analyses from its NOVA1 Phase 2 trial, including effects on cognition and negative symptoms.
Another recurring news theme is corporate and leadership developments. Recent press releases describe appointments to senior roles in regulatory affairs, commercial operations, corporate affairs, and people and culture, as well as inducement equity grants made under Nasdaq Listing Rule 5635(c)(4). These announcements provide context on how the company is building its internal capabilities to support later-stage development and potential future commercialization of LB-102.
LB Pharmaceuticals’ news flow also includes capital markets and index-related updates, such as its initial public offering of common stock and subsequent inclusion in the Russell 2000 and Russell 3000 indices. For investors tracking LBRX, this news page offers a consolidated view of regulatory filings referenced in press releases, clinical milestones, leadership changes, and other corporate developments that shape the company’s progress in neuropsychiatric drug development.
LB Pharmaceuticals (Nasdaq: LBRX) presented new Phase 2 NOVA-1 analyses at SIRS on March 27, 2026, showing LB-102 produced a statistically significant, dose-dependent improvement in global cognition that was primarily a direct drug effect rather than secondary to overall symptom change.
LB-102 is a once-daily oral selective D2/D3/5HT7 antagonist that showed benefit versus placebo across PANSS Marder factors, rapid onset at week 1, sustained effects through endpoint, and a favorable safety profile with low EPS, minimal sedation, and few GI side effects. The company plans cognition as a secondary endpoint in pivotal NOVA-2 and other trials.
LB Pharmaceuticals (Nasdaq: LBRX) reported positive Phase 2 results for LB-102 in acute schizophrenia and advanced LB-102 into late-stage development, initiating a Phase 3 NOVA-2 trial (topline H2 2027) and a Phase 2 bipolar depression trial (ILLUMINATE-1; topline Q1 2028).
The company completed an IPO raising $327.8 million, added a $100 million private placement, and reported cash, cash equivalents, and investments of $295.2 million as of December 31, 2025—expected to fund operations into Q2 2029.
LB Pharmaceuticals (Nasdaq: LBRX) initiated its pivotal Phase 3 trial NOVA-2 of LB-102 for schizophrenia on March 25, 2026. NOVA-2 will randomize ~460 patients 1:1:1 to 50 mg, 100 mg, or placebo for six weeks; primary endpoint is change in PANSS total score at Week 6.
Secondary endpoints include negative symptoms, cognitive performance, CGI-S, Marder factors, and PSP. An ~900-patient open-label extension is planned. Topline data are expected in 2H 2027; a pre-NDA meeting with FDA is expected if results are positive.
LB Pharmaceuticals (Nasdaq: LBRX) appointed Robert Lenz, M.D., Ph.D. to its Board of Directors on March 9, 2026. Dr. Lenz brings over 20 years of neuroscience R&D leadership, including senior roles at Neumora Therapeutics and Amgen, and a track record overseeing drug development through regulatory approval.
The appointment is positioned to support advancement of LB-102 into late-stage clinical development across multiple neuropsychiatric indications.
LB Pharmaceuticals (Nasdaq: LBRX) announced management will present at two investor events in March 2026: the Leerink 2026 Global Healthcare Conference on March 11, 2026 at 1:40 p.m. ET and the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 2:30 p.m. ET.
A live webcast and archived replay will be available in the Investors > Events section of the company website at https://lbpharma.us/.
LB Pharmaceuticals (Nasdaq: LBRX) granted an inducement equity award to new General Counsel Dr. Minako Pazdera on February 10, 2026 under the Nasdaq Listing Rule 5635(c)(4) exception.
Dr. Pazdera received options to buy 140,000 shares, with a 10-year term, $24.22 exercise price (closing price on grant date) and four-year vesting (25% after one year, then monthly).
LB Pharmaceuticals (Nasdaq: LBRX) entered a securities purchase agreement to sell 3,306,571 shares of common stock and pre-funded warrants to purchase up to 1,417,107 shares at $21.17 per share (pre-funded warrant price $21.1699), anticipating approximately $100.0 million gross proceeds.
The private placement is expected to close on or about February 6, 2026, includes major institutional investors, and names Leerink Partners, Piper Sandler and Stifel as placement agents. Proceeds are intended to fund a Phase 2 trial of LB-102 in major depressive disorder and for working capital; resale registration rights were agreed with investors.
LB Pharmaceuticals (Nasdaq: LBRX) initiated a randomized, double-blind Phase 2 ILLUMINATE-1 trial of oral LB-102 in bipolar 1 depression on Jan 26, 2026. The two-arm, six-week outpatient study will randomize ~320 patients 1:1 to LB-102 (pooled 25 mg or 50 mg once daily) or placebo across ~30 U.S. sites. The primary endpoint is MADRS-10 at week 6 with a primary analysis pooling doses vs placebo. Secondary measures include MADRS-6, CGI-BP, cognition, and anhedonia. Topline results are expected in 1Q 2028. Company also noted prior positive Phase 2 schizophrenia results and a Phase 3 schizophrenia program on track with H2 2027 results expected.
LB Pharmaceuticals (Nasdaq: LBRX) announced on January 21, 2026 the appointment of Dr. Minako Pazdera as General Counsel. Dr. Pazdera brings more than 25 years of experience in corporate governance, intellectual property, strategic transactions and compliance and will support advancement of LB-102 and the company’s CNS-focused strategy. Her background includes GC roles at Kardigan and Carmot Therapeutics, where she led legal work during a dual-track process that culminated in Carmot’s acquisition by Roche for up to $3.1 billion in 2024. She holds a J.D., a Ph.D. in biological sciences and a B.A. in molecular and cell biology.
LB Pharmaceuticals (Nasdaq: LBRX) granted inducement equity awards to two new senior hires on January 9, 2026 under the Nasdaq Listing Rule 5635(c)(4). The company awarded Ellen Rose options to purchase 100,000 shares and Lindsay Beaupre options to purchase 75,000 shares.
The options have a 10-year term, an exercise price of $20.73 per share (the closing price on the grant date), and vest over 4 years with 25% vesting after one year and the remainder vesting monthly in 1/48th increments, subject to continuous service.